Literature DB >> 9008447

Improved outcome of elderly patients (> or = 75 years of age) with acute myocardial infarction from 1981-1983 to 1992-1994 in Israel. The SPRINT and Thrombolytic Survey Groups. Secondary Prevention Reinfarction Israel Nifedipine Trial.

S Gottlieb1, U Goldbourt, V Boyko, G Barbash, L Mandelzweig, H Reicher-Reiss, S Stern, S Behar.   

Abstract

BACKGROUND: The number of elderly patients experiencing acute myocardial infarction (AMI) is growing rapidly, and their hospital mortality rate remains high, although mortality after AMI declined in the 1990s with the introduction of new therapeutic modalities. METHODS AND
RESULTS: We compared the management, in-hospital complications, and 30-day and 1-year mortality rates in two cohorts of elderly (> or = 75 years of age) AMI patients in the coronary care units in Israel before and after the reperfusion era. The first cohort of 789 consecutive patients was from the Secondary Prevention Reinfarction Israel Nifedipine Trial registry in 1981-1983; the second 366 patients came from two prospective nationwide surveys in 1992 and 1994. Reperfusion therapies were not used in 1981-1983 but were used in 1992-1994. The 30-day mortality rate declined from 38% in 1981-1983 to 27% in 1992-1994 (odds ratio, 0.49; 95% confidence interval [CI], 0.34 to 0.71), and the cumulative 1-year mortality rate declined from 52% to 38% (hazard ratio [HR], 0.62; 95% CI, 0.50 to 0.76). In the 1992-1994 cohort, the decline in mortality was most marked in patients reperfused by thrombolysis and/or percutaneous transluminal coronary angioplasty or coronary artery bypass graft surgery but was also evident in nonreperfused patients: cumulative 1-year mortality rate was 29% in the former (HR, 0.45; 95% CI, 0.31 to 0.67) and 42% in the latter (HR, 0.60; 95% CI, 0.46 to 0.78).
CONCLUSIONS: During the last decade, elderly (> or = 75 years) AMI patients experienced fewer in-hospital complications and lower 30-day and 1-year mortality rates, which declined approximately 30%, most markedly in reperfused patients. The favorable outcome in 1992-1994 was related to changes in patient management. Reperfusion therapy is therefore also advocated in elderly AMI patients, unless specific contraindications are present.

Entities:  

Mesh:

Year:  1997        PMID: 9008447     DOI: 10.1161/01.cir.95.2.342

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  Survival trends among Danish patients undergoing coronary angiography for known or suspected ischaemic heart disease: a population based follow up study, 1992-2000.

Authors:  S P Johnsen; J Videbaek; L Pedersen; R Steffensen; R Videbaek; T Niemann; T T Nielsen; H T Sørensen
Journal:  Heart       Date:  2005-04-06       Impact factor: 5.994

2.  Changing the site of delivery of thrombolytic treatment for acute myocardial infarction from the coronary care unit to the emergency department greatly reduces door to needle time.

Authors:  C T Hourigan; D Mountain; P E Langton; I G Jacobs; I R Rogers; G A Jelinek; P L Thompson
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

3.  Management and outcome of cardiogenic shock complicating acute myocardial infarction in hospitals with and without on-site catheterisation facilities.

Authors:  I M Barbash; S Behar; A Battler; D Hasdai; V Boyko; S Gottlieb; J Leor
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

Review 4.  Use of reperfusion therapies in elderly patients with acute myocardial infarction.

Authors:  B G Angeja; C M Gibson; R Chin; J G Canto; H V Barron
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  In-hospital and six-month outcomes of elderly patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.

Authors:  Fereydoon Noohi; Isa Hashemi; Hamid Reza Sanati; Mohammad Mehdi Peighambari; Majid Kiavar; Mohsen Maadani; Hossein Ali Bassiri; Ali Zahedmehr; Farshad Shakerian; Ata Firouzi; Reza Kiani; Seifollah Abdi
Journal:  ARYA Atheroscler       Date:  2016-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.